All In Biotech

NDA 215457 · Kaleo INC

Naloxone Hydrochloride (Autoinjector)

Naloxone Hydrochloride · Intramuscular, Subcutaneous

Priority reviewDiscontinued

Last checked: Nov 20, 2026Latest source record: Apr 3, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2022

Feb 28, 2022

Approved uses

1

Original approval plus efficacy supplements

Registered trials

682

129 Phase 3, 31 recruiting

FAERS reports

933

752 serious, 140 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Mar 11, 2022.

NALOXONE HYDROCHLORIDE injection is indicated for use by military personnel and chemical incident responders for: Emergency treatment of patients 12 years of age and older where use of high-potency opioids such as fentanyl analogues as a chemical weapon is suspected. Temporary prophylaxis of respiratory and/or central nervous system depression in military personnel and chemical incident responders entering an area contaminated with high-potency opioids such as fentanyl analogues. NALOXONE HYDROCHLORIDE injection is an opioid antagonist indicated for use by military personnel and chemical incident responders for: Emergency treatment of patients 12 years of age and older where use of high-potency opioids such as fentanyl analogues as a chemical weapon is suspected. ( 1 ) Temporary prophylaxis of respiratory and/or central nervous system depression in military personnel and chemical incident responders entering an area contaminated with high-potency opioids such as fentanyl analogues. ( 1 )

Mechanism: Naloxone HCl is an opioid antagonist that antagonizes opioid effects by competing for the same receptor sites. Naloxone HCl reverses the effects of opioids, including respiratory depression, sedation, and hypotension. Also, it can reverse the psychotomimetic and dysphoric effects of agonist-antagonists such as pentazocine.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Feb 28, 2022 Original approval · Type 5 - New Formulation or New Manufacturer · priority review LetterLabelReview
1 products under this application
  • NALOXONE HYDROCHLORIDE (AUTOINJECTOR) · NALOXONE HYDROCHLORIDE 10MG/0.4ML (10MG/0.4ML) · SOLUTION, INTRAMUSCULAR, SUBCUTANEOUS · Discontinued

Clinical trials

Interventional ClinicalTrials.gov studies with "Naloxone" as an intervention, any sponsor and status, largest first.

All 682 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective97
  • toxicity to various agents90
  • vomiting58
  • fatigue49
  • off label use49
  • overdose48
  • drug withdrawal syndrome46
  • nausea46
  • diarrhoea40
  • pain40
  • febrile neutropenia32
  • fall31

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20041
20051
20072
20083
200910
20108
20113
20129
20139
201410
201515
201626
201735
201859
201950
2020128
202185
2022106
202394
2024117
2025103
202659

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,733 on PubMed

Sponsor: Kaleo INC

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.